Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade
© Kumari and Garnett-Benson. 2016
Received: 17 November 2015
Accepted: 3 February 2016
Published: 13 February 2016
Sub-lethal doses of ionizing radiation (IR) can alter the phenotype of target tissue by modulating genes that influence effector T cell activity. Previous studies indicate that cancer cells respond to radiation by up-regulating surface expression of death receptors, cell adhesion molecules and tumor-associated antigens (TAA). However, there is limited information available regarding how T cells themselves are altered following these interactions with irradiated tumor cells.
Here, several human colorectal tumor cell lines were exposed to radiation (0–10 Gy) in vitro and changes in the expression of molecules costimulatory to effector T cells (4-1BBL, OX-40L, CD70, ICOSL) were examined by flow cytometry. T cell effector function was assessed to determine if changes in these proteins were directly related to the changes in T cell function.
We found OX-40L and 4-1BBL to be the most consistently upregulated proteins on the surface of colorectal tumor cells post-IR while ICOSL and CD70 remained largely unaltered. Expression of these gene products correlated with enhanced killing of irradiated human colorectal tumor cells by TAA-specific T-cells. Importantly, blocking of both OX-40L and 4-1BBL reversed radiation-enhanced T-cell killing of human tumor targets as well as T-cell survival and activation.
Overall, results of this study suggest that, beyond simply rendering tumor cells more sensitive to immune attack, radiation can be used to specifically modulate expression of genes that directly stimulate effector T cell activity.
KeywordsIonizing radiation Tumor immunity Cytotoxic T cells Immunogenic modulation Effector costimulation Colorectal
Radiotherapy (RT) is an extremely common modality in cancer treatment. Many cancer patients undergo RT during their course of illness however tumor cells acquire mutations during development that inhibit cell death by radiation . RT also fails to control systemic disease and many cancer patients experience disease recurrence . Moreover, radiation has significant dose limiting toxicities when used as a definitive therapy or in sensitive tissues such as the colon [3, 4]. Cancer immunotherapy (CIT) is emerging as an attractive therapeutic option and many standard cancer therapies, such as chemotherapy and radiation, rely on induction of functional immune cells for efficacy [5, 6]. Indeed, combination CIT and RT is more effective in treating metastatic and reoccurring cancers than either of the therapies alone [7–15]. Fully understanding the role of RT in tumor immunity will have a major impact on the treatment of cancers combining these modalities .
Effective cancer immunotherapy (CIT) strategies aim to generate tumor-specific CD8+ CTLs to attack and kill tumor cells [17, 18]. To elicit an effective immune response against tumors, the immune system needs to recognize tumor-associated antigen (TAA) presented to the TCR within MHC Class-I molecules, in conjunction with appropriate co-stimulation [19, 20]. Most cancer patients have some level of TAA-specific T cells. Surprisingly, treatments that further induce or expand the number of anti-TAA CTLs do not consistently translate into objective clinical tumor responses. As such, it is clear that that increasing tumor-specific CTL numbers is insufficient to control malignant cells and eliminate cancer. Several possibilities for this outcome include weak immunogenicity of TAA, low expression of co-stimulatory molecules on tumor cells and APCs, and/or secretion of suppressive molecules or recruitment of suppressive cells.
Local tumor irradiation has been shown to generate tumor-specific CTL and enhance anti-tumor immune responses [21–25]. Sub-lethal doses of ionizing radiation (IR), for example, have been reported to up-regulate expression of immune-stimulatory proteins in various tissue types both in vitro and in vivo [25, 26]. We previously reported that exposure of human carcinoma cell lines to sub-lethal radiation results in enhanced susceptibility to lysis by tumor specific cytotoxic T cells (CTLs) [26, 27]. Significantly enhanced killing by CEA-specific CD8+ CTLs was observed in five of five colorectal carcinoma (CRC) cell lines exposed to a single dose of 10 Gy radiation. Furthermore, enhanced attack by CTLs in head and neck squamous cell carcinoma  and prostate carcinoma  suggests the functional enhancement is not limited to a single antigen-specificity or cancer type. More recently we reported that irradiation of human tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways ; however, the differences in magnitude of lysis among the cell lines does not correlate with altered expression of death receptors, nor altered surface expression of MHC-I, ICAM-1 or TAAs . Thus, the mechanism of enhanced CTL killing against human carcinoma cells is unclear and surprisingly few studies focus on understanding the effect of radiation-induced changes in tumor cells on CTL effector activity and function.
Tumor derived antigens often induce insufficient co-stimulation and induce immune tolerance to the antigen. Antigen presentation in a toleragenic or immunosuppressive environment where robust costimulation is not present leads to sub-optimal immune responses such as T-cell anergy. T-cell co-stimulatory agonists can program T cells encountering these non-immunogenic antigens to expand and develop anti-tumor effector activities . As a result, strategies for improving positive co-stimulation to T cells and reversing negative regulation of T cells are currently very attractive therapeutic approaches for cancer therapy. The latter approach has resulted in recent FDA approval of several T cell checkpoint blockade agents. Regarding positive signals to T cell, the co-stimulatory molecules 4-1BB ligand (4-1BBL/TNFSF9/CD137L) and OX-40 ligand (OX-40L/TNFSF4/CD134L/CD252) are important regulators of CTL function, and lack of signaling through these molecules results in reduced CTL activity [20, 31–33]. In tumor bearing mice, intratumoral OX-40 activation increases CD40 expression on T cells and increases the effector memory T cells (TEM) subset . 4-1BBL (TNFRSF9/CD137) costimulation of tumor-specific T cells is important for T-cell activation and 4-1BBL transfected DCs elicit more effective responses and enhanced CTL killing of tumor cells, due to increased expression of perforin and IFN-γ . In recognition of the importance of these pathways to generating effective antitumor immunity, clinical studies have started to evaluate the effectiveness of humanized agonist antibodies to both OX-40 and 4-1BB [36–39]. Engagement of OX-40 and 4-1BB by agonist (activating) antibodies increases tumor immunity, resulting in long-term survival in a number of murine tumor models [32, 40–42]. These costimulatory signals may be particularly important for effective responses against self-antigen such as those expressed by many tumor cells. In the absence of these co-stimulatory signals anti-tumor effector T-cells may be rendered anergic.
Our previous studies suggest that sub-lethal doses of radiation cause altered expression of genes within tumor cells resulting in increased CTL-mediated lysis . More recently, we reported that radiation increased expression both OX-40L and 4-1BBL in human prostate cancer cells , and that increased expression of 4-1BBL in colorectal tumor cells occurred via epigenetic changes at the promoter . The present study was designed to test the hypothesis that enhanced activity of TAA-specific CTLs against tumor cells surviving radiation is mediated, in part, through increased effector co-stimulation from OX-40L and 4-1BBL on tumor cells. To our knowledge, this is the first study to (a) demonstrate that radiation specifically modulates OX-40L and 4-1BBL expression while leaving expression of other co-stimulatory molecules such as CD70 and ICOSL unchanged, (b) report OX-40L and 4-1BBL expression upregulated in a panel of colorectal cancer cell lines post-IR, (c) show that irradiated tumor cells that do not increase co-stimulatory molecule expression also do not increase T cell activity, and (d) determine that CTL killing of irradiated tumor cells is abolished in the presence of a neutralizing antibody against OX-40L and silenced 4-1BBL expression. Overall, the results of this study suggest that tumors surviving radiation therapy are not simply rendered more ‘sensitive to T cells attack’ but actively modulate expression of proteins that induce enhanced effector CTL function and activity.
Human colorectal carcinoma cell lines HCT116, Caco-2 and WiDr, were obtained from the laboratory of tumor immunology and biology, LTIB, NCI, NIH. SW620, HT-29, LS174T and Colo205 cells were purchased from ATCC. All cells were cultured as recommended by ATCC and tested periodically to ensure absence of Mycoplasma. Cells were incubated at 37 °C incubator with 5 % CO2. The use of these de-identified and commercially purchased cell lines received exempt approval under a human investigation protocol approved by the Institutional Review Board of Georgia State University (#H13305).
A RS-2000 biological X-ray irradiator (Rad source technology, Suwanee, GA) was used to irradiate tumor cells. Cells were irradiated at a dose rate of 2 Gy/min at voltage and current of 160 kV and 25 mA, respectively. Cells were maintained in suspension and kept on ice during irradiation. Immediately after irradiation, cells were centrifuged and cells were plated in tissue culture plates in fresh media.
At 24 or 48 h post-IR, RNA was extracted from tumor cells using RNeasy mini kit (Qiagen Inc. Valencia, CA) according to manufacturer’s instructions. Purified RNA was DNase-treated by Rnase-free DNase (Qiagen Inc. Valencia, CA) following manufacturer’s instructions.
Cells were stained with species-specific primary labeled mAb [CD137L (4-1BBL)-PE, CD252 (OX-40L)-PE, CD70-FITC, ICOSL-PE, CD8α-FITC, CD107a-APC, CD25-APC, CD69-PE, CD66-PE, CD227 (MUC-1)-FITC] purchased from BioLegend or BD biosciences (San Diego, CA). Surface staining was done in cell staining buffer for 30 min on ice. 7AAD dye were obtained from BD biosciences (San Diego, CA) and used according to manufacturers instructions to measure cell death. Intracellular staining of active caspase-3 was done according to manufacturer’s instruction. Flow cytometry data were acquired on BD Fortessa and analyzed with FlowJo software (TreeStar). The live cells population was gated on the FSC and SSC scatter plots for analysis of surface proteins. No live cells gate was used for cell death analysis samples. Samples were stained with the appropriate isotype control antibodies and gates were set to less than 5 % in all isotype control samples.
Generation of cytotoxic T-lymphocytes
Cell-rich leukapheresis collections from HLA-A2+ donors were obtained from Hemacare (Van Nuys, CA), with appropriate informed consent, for generating antigen specific CTLs as previously described [27, 45, 46]. These commercially purchased (and de-identified) tissues received exempt approval under a human investigation protocol approved by the Institutional Review Board of Georgia State University (#H13305). Briefly, PMBCs that adhered to the tissue culture flask after 2 h were cultured for 7 days in AIM-V media (Invitrogen) containing 100 ng/ml of human granulocyte colony stimulating factor (GM-CSF) and 20 ng/ml of IL-4 (Miltenyi Biotec, Inc. Auburn, CA). On the fifth day in culture 500 ng/ml CD40L (Millipore corporation, Temecula, CA) was added to mature the DCs. Matured DCs were then collected and loaded with 40 μg/mL of HLA-A2 binding peptides. CEA peptide (YLSGANLNL (CAP-1; ) or MUC (ALWGQDVTSV) peptides were allowed to bind to the DCs for 4 h in a 37 °C 5 % CO2 incubator. and subsequently irradiated with 50 Gy. Immunomagnetic beads (Miltenyi Biotec Inc. Auburn, CA) were used to isolate CD8+ T cells from the non-adherent fraction of PBMCs. The peptide pulsed DCs were used to stimulate CD8+ T cells in media containing 10 ng/ml of IL-7 (Millipore, Temecula, CA). After 3 days in culture 30U/ml of IL2 (Millipore, Temecula, CA) were added. T-cells were restimulated in this manner weekly using autologous antigen presenting cells. On the fourth day of stimulation T cells were isolated and used in a standard cytotoxic killing assay.
CTL lysis of HCT116, SW620, Colo205, and LS174T (HLA-A2-) tumor cells was measured using the DELFIA cell cytotoxicity kit (Perkin Elmer). Seventy two hour after irradiation, viable and proliferating tumor cells (2 × 106/2 ml) were harvested, counted, and incubated with 5 μl of BATDA (bis (acetoxymethyl) 2,2′:6′,2′′- terpyridine- 6,6′′- dicarboxylate; PerkinElmer, Boston, MA) for 20 min at 37 °C. After incubation, cells were washed four times with PBS. 5 × 103 cells were added in triplicate to a 96-well U-bottom plate, and either CEA or MUC specific CD8+ T-cell were added to the wells (E:T ratios between 12:1 and 30:1) and incubated for 4–5 h at 37 °C. After incubation, the plate was centrifuged (500g for 5 min) and 20 μl of supernatant were transferred into a flat bottom plate. Two hundred microlitre of Europium solution was added and incubated for 15 min at room temperature on plate shaker . Lysis was measured on a time resolved Victor3 plate reader fluorometer. The percentage of tumor lysis was calculated as follows: % tumor lysis = experimental release (counts) − spontaneous release (counts)/maximum release (counts) − spontaneous release (counts) × 100.
Expression knock-down and blocking
4-1BBL gene expression was knocked down using a gene specific siRNA. Briefly, tumor cells were plated in a 6-well dish at 1 × 105 cells/well 1 day prior to transfection, with 50–70 % confluence on the day of transfection. In some experiments 2 × 104 cells were plated in 24-well plates. 4-1BBL Flexi Tube siRNA #6 (Qiagen Inc. Valencia, CA) was diluted in optiMEM medium (invitrogen) and transfected using Hyperfect (Qiagen Inc. Valencia, CA). Twenty-four hours post transfection; cells were irradiated with 10 Gy or mock-irradiated. The cells were harvested 24–48 h post irradiation and 4-1BBL mRNA expression was measured. A negative control siRNA that was not specific to 4-1BBL was also transfected into cells and 4-1BBL mRNA similarly evaluated. Using combination 4-1BBL and OX-40L siRNA to knock down both genes simultaneously resulted in incomplete knock-down of both genes in our tumor cells. As a result, for dual blockade experiments, we knocked down 4-1BBL using siRNA and we used a Goat anti-human OX-40L-neutralizing antibody (R&D system, Minneapolis, MN) to block OX-40 ligand and receptor interaction (cat #: AF1054). In the indicated groups, 500 ng/ml of anti-human OX-40L neutralizing antibody was added to Eu-labeled tumor cells for 15 min prior to adding TAA-specific CTLs. The anti–human 4-1BB monoclonal blocking antibody BBK-2  was added 20 μg/ml 15 min before T-cells were added. Isotype matched antibodies were added to the other groups as a negative control. In parallel experiments, the percent of T cells expressing CD25 (activation) or positive for active Caspase-3 (cell death) was measured by flow-cytometry as previously described .
Statistical difference in the distribution of flow cytometric data from several repeat experiments were graphed and the mean of three to four independent experiments were calculated and an un-paired two-tailed student T-test was performed using Graphpad by Prism. Statistical differences between groups in the cytolysis assays, activation, and survival assays were calculated using un-paired one or two-tailed student T-test and calculated for the 95 % confidence interval (CI).
Results and discussion
Sub-lethal irradiation of colorectal carcinoma cell lines does not modulate all T cell stimulatory molecules the same
Sub-lethal irradiation of most human colorectal carcinoma cell lines enhances OX-40L and 4-1BBL expression
Sub-lethal irradiation increases CEA and MUC-specific cytotoxic T-cell mediated killing of HCT116 and SW620 cells, but not of Colo205 cells
Though HCT116 and SW620 cells modulate OX-40L and 4-1BBL post-IR and Colo205 cells do not, it is unclear what is responsible for the variable magnitude of cytolysis among the cell lines examined. These differences, however, do not appear to correlate with altered surface expression patterns of MHC-I or TAA. Specifically, HCT116 cells are killed post-IR while Colo205 cells are not (Fig. 4a, c). This occurs despite the fact that Colo205 cells express more MHC molecules per cell than HCT116 cells, as determined by both mean fluorescence intensity (MFI) (255 vs 226 respectively) and percent positive cells (74.6 vs 99.5 %) (Fig. 4e). SW620 and HCT116 cells demonstrate similarly enhanced cytolysis by CEA-specific CTLs post-IR (Fig. 4a). SW620 cells express more MHC-I (MFI 302) than HCT116, however, they actually decrease the amount of surface CEA (93 vs 85.3 %). All four cell lines were greater than 95 % positive for Pan MHC class I detected using and HLA-ABC antibody (data not shown), however LS174T were less than 5 % positive for HLA-A2. Though the impact of radiation on antigen processing and presentation remains under study, increased antigen presentation in a toleragenic or immunosuppressive environment where robust costimulation is not present could still lead to sub-optimal immune responses.
4-1BBL and OX-40L dual co-stimulation is required for radiation-enhanced sensitivity to CTL killing
There is a wide array of CIT strategies under clinical investigation in combination with RT for the treatment of advanced cancers. With the exception of studies using RT for lymphodepletion prior to adoptive cell transfer , most clinical investigations utilize RT as an adjuvant to immune-based therapies [13–15]. These studies demonstrate enhanced immune responses, including expanded numbers of circulating anti-tumor CTLs and antibodies in treated patients. Unfortunately, these increased immune responses have not translated to a significant reduction in tumor burden often enough [14, 56, 57] and the reasons for this unexpected lack of clinical response have yet to be resolved. Detailed investigation into the molecular mechanism that results in the ability of IR to enhance anti-tumor immune responses will be required to capitalize on these biological changes and allow for additional opportunities for eliminating advanced stage cancers. More recently, modulation of tumor cells by RT has come into the spotlight and it has become clear that cells surviving radiation have an altered phenotype that can be exploited by CIT approaches [43, 58, 59]. To our knowledge, our study reports for the first time that human colorectal cells surviving radiation modulate expression of both OX-40L and 4-1BBL, and that irradiated tumor cells promote CTL tumoricidal activity related to these changes.
Our previous CTL killing assays were done using CTLs against a single antigen specificity (CEA) and a single dose (10 Gy) . In our current study, killing activity of both CEA-specific and MUC-specific T cells was enhanced, suggesting that radiation-enhanced lysis is not limited to a single antigen specificity or tumor cell line (Fig. 1). We also detected enhanced susceptibility to CTL killing in tumor cells treated with a lower dose (5 Gy) of radiation. We observed enhanced CTL activity against some tumor cells treated with radiation and wondered if other aspects of T-cell biology were differentially altered in tumor cells killed (HCT116 and SW620) versus not killed post-IR (Colo205). We reasoned that T cells capable of surviving longer after interacting with tumor cells would be more likely to have productive interactions with tumor cells resulting in enhanced ability to kill tumor cells. Very few dead T cells were detected in cultures of T cells alone; however, there was an increase in T-cell death upon incubation with untreated tumor cells (Fig. 6). Death of T-cells following interaction with tumor cells has been reported by others, and is thought to be caused by tumor expressed PDL1, FasL and/or activation induced cell death (AICD) [60–62]. Surprisingly, we detected a decrease in the number of dead T cells (Fig. 6) if the tumor cells had been treated with radiation as compared to non-irradiated cells .
As both OX-40L and 4-1BBL have been reported to enhance T-cell survival and T-cell activation [38, 48, 63, 64], we next evaluated their expression in a panel of tumor cells. We found that five of six CRC tumor cell lines increased surface expression of both OX-40L (Fig. 2), and 4-1BBL protein (Fig. 3) after treatment with 10 Gy of ionizing radiation. Though non-treated tumor cells expressed variable amounts of both OX-40L and 4-1BBL on their cells surface, this rarely exceeded 20 % in our experiments. Salih et al. (2000) measured 4-1BBL expression on carcinoma cells and found that HCT116 cells expressed higher levels than HT-29 cells, which is in agreement with our observations in untreated tumor cells (Fig. 3b; gray bars). In contrast to OX-40L and 4-1BBL, radiation did not increase the expression of other co-stimulatory molecules evaluated in this study, including CD70, ICOSL and B7-1 (Fig. 1). The mechanism of selective gene expression is under continued investigation, and data from our lab suggests that radiation is epigenetically regulating expression of 4-1BBL and OX-40L . Tumor cells irradiated in vitro may respond to radiation differently than tumors irradiated in vivo due to the influence of the microenvironment and validation of these changes in vivo is currently under study.
To determine if radiation-induced expression of OX-40L and 4-1BBL plays a direct role in enhanced tumor cell susceptibility to lysis by CTLs, we conducted CTL cytolysis experiments in combination with molecular inhibition. We found that neither knocking down 4-1BBL in tumor cells, nor inhibiting OX-40L signaling independently, completely reversed radiation-enhanced sensitivity to cytolysis (Fig. 5b). However, when both molecules were inhibited there was a more prominent loss of the radiation-enhanced killing of both SW620 and HCT116 cells by T cells (Figs. 5b and 6b), and reduced CD25 expression (Fig. 5c) and survival (Fig. 6c) of T cells. Both 4-1BBL and OX-40L signals have been reported by others to increase the production of effector molecules such as perforin and granzyme in stimulated CTLs [50, 52]. Whether irradiated tumors are impacting production or release of effector molecules from CTLs is currently under investigation. Ongoing mechanistic studies are evaluating which mechanism (increased survival or increased production/release of effector molecules or both) is primarily responsible for enhanced tumoricidal activity, as well as the relative contribution of each co-stimulatory molecule following both in vivo and in vitro tumor cell irradiation. Others have recently reported that radiation increases antigen processing and presentation pathways within tumor cells . Antigen processing and presentation were not directly assessed here, however, changes in MHC-I and TAA levels in the current study did not appear to noticeably align with the changes observed in T cell activities (Fig. 4e). Given the levels of TAA and HLA-A2 among the cells lines it is difficult to imagine SW620 and HCT116, but not Colo205 cells, enhance antigen processing and presentation of CEA and MUC-1 HLA-A2 restricted peptides. Particularly when Colo205 cells and HCT116 cells express comparable amounts of CEA post-IR, and the frequency (99.5 vs 74.6 %) of HLA-A2-expressing HCT116 cells actually decreases post-IR (Fig. 4e). While the impact of radiation on antigen processing and presentation in human tumor cells remains under worthwhile investigation, it remains likely that altered antigen presentation will work in concert with other tumor changes.
The aims of this study were meant to provide data to support the growing use, and rationale application, of RT in combination with CIT. If IR-modulated expression of 4-1BBL and OX-40L is shown to play a significant role in the ability of RT to enhance effector CTL killing, this could be an alternative therapeutic approach to enhancing these important T-cell signals. This approach is particularly relevant given the severe toxicity that can occur when using agonistic antibodies. Furthermore, the use of agonist antibodies is not limited to tumor-specific T-cells and, as a result, non-tumor specific T cells can become activated and induce off-target effects. Using RT to induce these molecules, specifically on a focused target, represents a refinement in the approach by triggering these pathways in anti-tumor CTLs infiltrating irradiated tumors. Ongoing investigations include determining the impact of RT on tumor modulation in vivo more comprehensively to assess the specificity of changes on tumor cells versus other cells in the microenvironment. We have previously reported on such “immunogenic modulation” (occurring in the absence of “immunogenic cell death”) following treatment of human tumor cells with docetaxel chemotherapy . Utilization of such direct tumor cell to T-cell mechanisms from phenotypically altered tumor cells that do not die post-IR, in addition to enhanced “danger” signals from dying cells, should allow for synergy resulting in a more robust anti-tumor immune attack. Ultimately, if immunomodulation of tumor cells by IR is shown to have a profound and consistent effect on CTL activity this would provide support for using IR, along with CIT strategies, specifically to enhance signals to these cells and optimize anti-tumor CTL responses.
CGB conceived of the study and AK helped design experiments. AK and CGB performed the human tumor T cell assays. AK and CGB analyzed data, prepared figures and wrote the manuscript. All authors read and approved the final manuscript.
This work was supported by an award from the National Cancer Institute, NIH (CA162235). This work was also supported in part by a Research Scholar Award (RSG-15-182-01-LIB) from the American Cancer Society and a Research Initiation Grant from Georgia State University. The authors would like to thank Melissa Heffner for help in editing the manuscript.
Previously published under Garnett C.T.
The authors declare no competing financial interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park). 2008;22(9):1064–70; discussion 1075, 1080–1061, 1084.Google Scholar
- Kumar S, Juresic E, Barton M, Shafiq J. Management of skin toxicity during radiation therapy: a review of the evidence. J Med Imaging Radiat Oncol. 2010;54(3):264–79.View ArticlePubMedGoogle Scholar
- Yeoh E. Radiotherapy: long-term effects on gastrointestinal function. Curr Opin Support Palliat Care. 2008;2(1):40–4.View ArticlePubMedGoogle Scholar
- Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Investig. 2008;118(6):1991–2001.PubMed CentralView ArticlePubMedGoogle Scholar
- Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(2 Pt 1):728–34.PubMedGoogle Scholar
- Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother. 2010;33(8):798–809.PubMed CentralView ArticlePubMedGoogle Scholar
- Ferrara TA, Hodge JW, Gulley JL. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr Opin Mol Ther. 2009;11(1):37–42.PubMed CentralPubMedGoogle Scholar
- Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N, Lan L, Dewyngaert JK, Zagzag D, McBride WH, et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res. 2006;12(15):4730–7.View ArticlePubMedGoogle Scholar
- Yokouchi H, Chamoto K, Wakita D, Yamazaki K, Shirato H, Takeshima T, Dosaka-Akita H, Nishimura M, Yue Z, Kitamura H, et al. Combination tumor immunotherapy with radiotherapy and Th1 cell therapy against murine lung carcinoma. Clin Exp Metastasis. 2007;24(7):533–40.View ArticlePubMedGoogle Scholar
- Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004;64(12):4328–37.View ArticlePubMedGoogle Scholar
- Hillman GG, Xu M, Wang Y, Wright JL, Lu X, Kallinteris NL, Tekyi-Mensah S, Thompson TC, Mitchell MS, Forman JD. Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Hum Gene Ther. 2003;14(8):763–75.View ArticlePubMedGoogle Scholar
- Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother. 2005;28(2):129–35.View ArticlePubMedGoogle Scholar
- Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res. 2008;14(16):5284–91.PubMed CentralView ArticlePubMedGoogle Scholar
- Kaufman HL, Divgi CR. Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination. Clin Cancer Res. 2005;11(19 Pt 1):6757–62.View ArticlePubMedGoogle Scholar
- Garnett-Benson C, Hodge JW, Gameiro SR. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol. 2015;25(1):46–53.PubMed CentralView ArticlePubMedGoogle Scholar
- Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–48.View ArticlePubMedGoogle Scholar
- Blattman J, Greenberg P. Cancer immunotherapy: a treatment for the masses. Science. 2004;305(5681):200–5.View ArticlePubMedGoogle Scholar
- Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol. 2010;37(5):524–32.PubMed CentralView ArticlePubMedGoogle Scholar
- Kroczek RA, Mages HW, Hutloff A. Emerging paradigms of T-cell co-stimulation. Curr Opin Immunol. 2004;16(3):321–7.View ArticlePubMedGoogle Scholar
- Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010;70(7):2697–706.View ArticlePubMedGoogle Scholar
- Chakravarty PK, Guha C, Alfieri A, Beri V, Niazova Z, Deb NJ, Fan Z, Thomas EK, Vikram B. Flt3L therapy following localized tumor irradiation generates long-term protective immune response in metastatic lung cancer: its implication in designing a vaccination strategy. Oncology. 2006;70(4):245–54.View ArticlePubMedGoogle Scholar
- Formenti SC, Demaria S. Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol. 2008;26(9):1562–63; author reply 1563.Google Scholar
- Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170(12):6338–47.View ArticlePubMedGoogle Scholar
- Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des. 2002;8(19):1765–80.View ArticlePubMedGoogle Scholar
- Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64(21):7985–94.View ArticlePubMedGoogle Scholar
- Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res. 2006;12(6):1897–905.PubMed CentralView ArticlePubMedGoogle Scholar
- Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res. 2008;14(13):4241–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Ifeadi V, Garnett-Benson C. Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS One. 2012;7(2):e31762.PubMed CentralView ArticlePubMedGoogle Scholar
- Adler AJ, Vella AT. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology. 2013;2(1):e22837.PubMed CentralView ArticlePubMedGoogle Scholar
- Kober J, Leitner J, Klauser C, Woitek R, Majdic O, Stockl J, Herndler-Brandstetter D, Grubeck-Loebenstein B, Reipert BM, Pickl WF, et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol. 2008;38(10):2678–88.PubMed CentralView ArticlePubMedGoogle Scholar
- Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23–68.View ArticlePubMedGoogle Scholar
- Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006;211:81–92.View ArticlePubMedGoogle Scholar
- Burocchi A, Pittoni P, Gorzanelli A, Colombo MP, Piconese S. Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells. Eur J Immunol. 2011;41(12):3615–26.View ArticlePubMedGoogle Scholar
- Song Z, Guo C, Li Y, Tan B, Fan L, Xiao J. Enhanced antitumor effects of a dendritic cell vaccine transfected with gastric cancer cell total RNA carrying the 4-1BBL gene in vitro. Exp Ther Med. 2012;3(2):319–23.PubMed CentralPubMedGoogle Scholar
- Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol Rev. 2011;244(1):218–31.PubMed CentralView ArticlePubMedGoogle Scholar
- Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Muller A, Pachynski R, Czerwinski D, Coutre S, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423–32.PubMed CentralView ArticlePubMedGoogle Scholar
- Garber K. Beyond ipilimumab: new approaches target the immunological synapse. J Natl Cancer Inst. 2011;103(14):1079–82.View ArticlePubMedGoogle Scholar
- Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol. 2010;37(5):508–16.View ArticlePubMedGoogle Scholar
- Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS, Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(6):682–5.View ArticlePubMedGoogle Scholar
- Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, et al. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. Journal of immunology. 2006;176(2):974–83.View ArticleGoogle Scholar
- Lee SJ, Myers L, Muralimohan G, Dai J, Qiao Y, Li Z, Mittler RS, Vella AT. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol. 2004;173(5):3002–12.View ArticlePubMedGoogle Scholar
- Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm. 2014;29(4):153–61.PubMed CentralView ArticlePubMedGoogle Scholar
- Kumari A, Cacan E, Greer SF, Garnett-Benson C. Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells. J Immunother Cancer. 2013;1:17.PubMed CentralView ArticlePubMedGoogle Scholar
- Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995;87(13):982–90.View ArticlePubMedGoogle Scholar
- Tsang KY, Zhu M, Nieroda CA, Correale P, Zaremba S, Hamilton JM, Cole D, Lam C, Schlom J. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen. Clin Cancer Res. 1997;3(12 Pt 1):2439–49.PubMedGoogle Scholar
- Bohlen H, Manzke O, Engert A, Hertel M, Hippler-Altenburg R, Diehl V, Tesch H. Differentiation of cytotoxicity using target cells labelled with europium and samarium by electroporation. J Immunol Methods. 1994;173(1):55–62.View ArticlePubMedGoogle Scholar
- Lee HW, Park SJ, Choi BK, Kim HH, Nam KO, Kwon BS. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol. 2002;169(9):4882–8.View ArticlePubMedGoogle Scholar
- Salih HR, Kosowski SG, Haluska VF, Starling GC, Loo DT, Lee F, Aruffo AA, Trail PA, Kiener PA. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol. 2000;165(5):2903–10.View ArticlePubMedGoogle Scholar
- Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, Weber J, Hwu P, Radvanyi L. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013;8(4):e60031.PubMed CentralView ArticlePubMedGoogle Scholar
- Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 2003;14(3–4):265–73.View ArticlePubMedGoogle Scholar
- Walch M, Rampini SK, Stoeckli I, Latinovic-Golic S, Dumrese C, Sundstrom H, Vogetseder A, Marino J, Glauser DL, van den Broek M, et al. Involvement of CD252 (CD134L) and IL-2 in the expression of cytotoxic proteins in bacterial- or viral-activated human T cells. J Immunol. 2009;182(12):7569–79.View ArticlePubMedGoogle Scholar
- Pule MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12(5):933–41.View ArticlePubMedGoogle Scholar
- Morales-Kastresana A, Fernandez de Sanmamed M, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa MC, Roauzaut A, et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res. 2013;19:6151–62.View ArticlePubMedGoogle Scholar
- Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26(32):5233–9.PubMed CentralView ArticlePubMedGoogle Scholar
- Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11(9):3353–62.View ArticlePubMedGoogle Scholar
- Nesslinger NJ, Sahota RA, Stone B, Johnson K, Chima N, King C, Rasmussen D, Bishop D, Rennie PS, Gleave M, et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res. 2007;13(5):1493–502.View ArticlePubMedGoogle Scholar
- Makinde AY, John-Aryankalayil M, Palayoor ST, Cerna D, Coleman CN. Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy. Mol Cancer Res. 2013;11(1):5–12.PubMed CentralView ArticlePubMedGoogle Scholar
- Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5(2):403–16.PubMed CentralView ArticlePubMedGoogle Scholar
- Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol. 1999;162(6):3273–9.PubMed CentralPubMedGoogle Scholar
- Prado-Garcia H, Romero-Garcia S, Morales-Fuentes J, Aguilar-Cazares D, Lopez-Gonzalez JS. Activation-induced cell death of memory CD8+ T cells from pleural effusion of lung cancer patients is mediated by the type II Fas-induced apoptotic pathway. Cancer Immunol Immunother. 2012;61(7):1065–80.View ArticlePubMedGoogle Scholar
- Chiou SH, Sheu BC, Chang WC, Huang SC, Hong-Nerng H. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol. 2005;67(1–2):35–50.View ArticlePubMedGoogle Scholar
- Mousavi SF, Soroosh P, Takahashi T, Yoshikai Y, Shen H, Lefrancois L, Borst J, Sugamura K, Ishii N. OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells. J Immunol. 2008;181(9):5990–6001.PubMed CentralView ArticlePubMedGoogle Scholar
- Habib-Agahi M, Jaberipour M, Searle PF. 4-1BBL costimulation retrieves CD28 expression in activated T cells. Cell Immunol. 2009;256(1–2):39–46.View ArticlePubMedGoogle Scholar
- Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133:624–36.PubMed CentralView ArticlePubMedGoogle Scholar